These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27423185)

  • 21. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of generic substitution on price competition in Finland.
    Aalto-Setälä V
    Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generic drug prescriptions following hospital discharge: a prospective study in France.
    Chu C; Rudant E; Bonvalet M; Agostini H; Cavalié P; Bonhomme-Faivre L; Frenkiel J; Taillandier J; Boissonnas A; Vittecoq D; Wyplosz B
    Eur J Intern Med; 2011 Oct; 22(5):e45-9. PubMed ID: 21925042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991-2008.
    Kelton CM; Chang LV; Guo JJ; Yu Y; Berry EA; Bian B; Heaton PC
    Appl Health Econ Health Policy; 2014 Apr; 12(2):165-77. PubMed ID: 24550087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia.
    Simoens SR
    Med J Aust; 2011 Jan; 194(1):52-3; author reply 53-4. PubMed ID: 21449876
    [No Abstract]   [Full Text] [Related]  

  • 26. Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.
    Hill A; Redd C; Gotham D; Erbacher I; Meldrum J; Harada R
    BMJ Open; 2017 Jan; 7(1):e011965. PubMed ID: 28110283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics and Price Increases Among Sole-Source, Off-Patent Drugs in the United States, 2008 to 2018.
    Alpern JD; Shahriar AA; Xi M; Thapa S; Kodet AJ; Stauffer WM; Vazquez Benitez G; Pawloski PA; Dehmer SP
    JAMA Netw Open; 2020 Aug; 3(8):e2013595. PubMed ID: 32804216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Easy cuts, easy rebound: Drug expenditures with massive price cuts in Korea.
    Kwon HY; Bae S; Choi SE; Park S; Lee EK; Park S; Kim J
    Health Policy; 2019 Apr; 123(4):388-392. PubMed ID: 30503763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evolution of reimbursement of high-cost anticancer drugs: Financial impact within a university hospital].
    Baudouin A; Fargier E; Cerruti A; Dubromel A; Vantard N; Ranchon F; Schwiertz V; Salles G; Souquet PJ; Thomas L; Bérard F; Nancey S; Freyer G; Trillet-Lenoir V; Rioufol C
    Bull Cancer; 2017 Jun; 104(6):538-551. PubMed ID: 28237353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do generics offer significant savings to the UK National Health Service?
    Kanavos P
    Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.
    Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D
    Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measuring performance in off-patent drug markets: a methodological framework and empirical evidence from twelve EU Member States.
    Kanavos P
    Health Policy; 2014 Nov; 118(2):229-41. PubMed ID: 25201433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. US Food and Drug Administration Disruption of Generic Drug Market Increases Hospital Costs.
    Almeter PJ; Labuhn JA; Morris PE; Hessel EA
    Anesth Analg; 2018 Dec; 127(6):1414-1420. PubMed ID: 29944521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of Medicine Prices in New Zealand and 16 European Countries.
    Vogler S; Kilpatrick K; Babar ZU
    Value Health; 2015 Jun; 18(4):484-92. PubMed ID: 26091603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Generic and biosimilar drug substitution: a panacea?].
    Daly MJ; Guignard B; Nendaz M
    Rev Med Suisse; 2015 Oct; 11(490):1909-12, 1914. PubMed ID: 26665661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Price survey. Generic drug market heats up.
    Hosp Mater Manage; 2001 Mar; 26(3):1, 12-3. PubMed ID: 11975141
    [No Abstract]   [Full Text] [Related]  

  • 38. The impact of price-cap regulations on market entry by generic pharmaceutical firms.
    Zhang W; Sun H; Guh D; Anis AH
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):231-238. PubMed ID: 27936981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of Spanish generic medicines retail market: recommendations to enhance long-term sustainability.
    Dylst P; Vulto AG; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):345-53. PubMed ID: 24758569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries.
    Leopold C; Mantel-Teeuwisse AK; Vogler S; de Joncheere K; Laing RO; Leufkens HG
    Health Policy; 2013 Oct; 112(3):209-16. PubMed ID: 24060335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.